Effects of Lenvatinib treatment for advanced differentiated thyroid cancer on cortisol deficiency
Our findings suggest a higher occurrence of PAI, which may contribute to fatigue associated with Lenvatinib treatment. Routine adrenal function testing and early recognition of PAI are essential for timely diagnosis and effective glucocorticoid replacement therapy, enabling patients to continue Lenvatinib treatment with improved tolerability and adherence.
Authors
- Fedra Mori
- B. Fazzalari
- Maria Grazia Deiana
- Valerio Renzelli (ORCID: https://orcid.org/0009-0000-3287-7737)
- Maurizio Poggi
- Claudia Bongermino
- Maria Francesca Lioni
- Salvatore Monti
- Giuseppe Pugliese
Institutions
- Azienda Ospedaliera Sant'Andrea (IT)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fendo.2025.1691740
- Primary Topic
- Thyroid Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00